Audit 290467

FY End
2023-06-30
Total Expended
$2.71M
Findings
0
Programs
6
Organization: Baruch S. Blumberg Institute (PA)
Year: 2023 Accepted: 2024-02-14
Auditor: Eisneramper LLP

Organization Exclusion Status:

Checking exclusion status...

Findings

No findings recorded

Programs

ALN Program Spent Major Findings
93.RD Development of An Oral Available Antiviral Drug for Yellow Fever $1.38M Yes 0
12.420 Military Medical Research and Development $473,506 Yes 0
93.855 Allergy, Immunology and Transplantation Research $99,857 Yes 0
93.395 Cancer Treatment Research $92,248 Yes 0
93.837 Cardiovascular Diseases Research $55,998 Yes 0
93.393 Cancer Cause and Prevention Research $18,149 Yes 0

Contacts

Name Title Type
NAYCKSJB7F68 Patti McAloon Auditee
2154894911 Jimmy Mo Auditor
No contacts on file

Notes to SEFA

Accounting Policies: The accompanying supplementary schedule of expenditures of federal awards ("schedule") includes the federal grant activity of Baruch S. Blumberg Institute and Subsidiary under programs of the federal governments for the year ended June 30, 2023. The information in this schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards ("Uniform Guidance"). Because the schedule presents only a selected portion of the operations of Baruch S. Blumberg Institute and Subsidiary, it is not intended to, and does not, present the financial position, changes in net assets, or cash flows of Baruch S. Blumberg Institute and Subsidiary. Expenditures reported on the schedule of expenditures of federal and state awards are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. De Minimis Rate Used: N Rate Explanation: Auditee used agreed upon rates in contract and grant agreements.